走向自然积极的路线图：制药行业的基础

of contentsTable a business imperative3Nature Action:01. pharmaceutical sector15Foundations for the03. Nature matters for business4Nature risks have shifted global policy5Nature positive and current business approaches6Catalyzing critical business action in support ofnature positive8 Stage 1:Assess (materiality screening)16Stage 2:Commit and Transform(targets for priority actions)30Stage 3:Disclose (initial disclosures)40 Roadmaps toNature Positive41Next steps for the04. Foundations for the pharmaceutical sectorfor the pharmaceuticalsector9Introducing the Roadmap02. Annexes05. 43 Context: Importance of nature to thepharmaceutical sector10 Scope of the Roadmap13 a business imperativeNature Action:01. Nature Action:a business imperative01. Efforts to protect and restore nature must activelyinvolve local communities and stakeholders. Thisprinciple is a key aspect of theKunming-MontrealGlobal Biodiversity Framework(GBF), particularly underTarget 19, which stresses the importance of inclusiveand participatory action. Engaging communitiesand stakeholders fosters the development of locallyadapted solutions, ensuring that conservation andrestoration efforts are effective and enhance theresilience and livelihoods of those who depend on theseecosystems. Similarly, Target 13 focuses on sharingof benefits from genetic resources, including digitalsequence information (DSI) and contributing to theGBF’s successful implementation by recognizing the roleplayed by those who protect biodiversity and preservetraditional knowledge.4 frameworks, the pharmaceutical sector engages withaccess and benefit-sharing processes as required bytheNagoya Protocol and the CBD, supporting effortsto ensure fair and transparent contributions tobiodiversity conservation. Nature matters for business Nature forms the foundation of the global economy, asall businesses rely on it to varying degrees. Societiescannot endure, much less prosper, without the vitalservices provided by the natural world – clean air, water,food and a stable planetary system. As global discussions on benefit-sharing continueto evolve, it will be important to refine mechanismsto ensure that they do not hinder innovationwhile recognizing the contributions of countriesand communities that provide access to theseresources. Strengthening collaboration amongresearchers, industry, and stakeholders will becritical to fostering the sustainable and responsibleuse of genetic materials, ensuring alignment withinternational biodiversity frameworks and equitabledevelopment goals. And yet, the ongoing and accelerating depletion ofnature is one of the greatest risks that humanity facestoday. Humanity is using double the resources that theEarth can regenerate each year.¹ This unsustainableuse, coupled with changes in land and sea use, pollutionand greenhouse gas (GHG) emissions, is drivingunprecedented levels of biodiversity loss.² Foundations for the pharmaceutical sectorThe loss of nature is already affecting businesses, bothdirectly and indirectly. Industries with high to moderatedependence on nature – those that depend significantlyon the extraction of resources from land, freshwater andoceans – account for more than half of global GDP.³ The Convention on Biological Diversity (CBD)decisionon the fair and equitable sharing of benefits fromthe use of DSI on genetic resources established avoluntary fund to enable companies to share benefitsarising from the use of DSI. Known as the Cali Fund,the indicative contribution rates are currently underreview – along with several other elements – as part ofongoing intergovernmental discussions to refine benefit-sharing mechanisms. In alignment with international The solutions needed are not incremental adjustments toexisting business models. Achieving WBCSD’sVision 2050and enabling more than 9 billion people to live well andwithin planetary boundaries requires the transformationof societies and economies.5 Addressing the climate crisis, restoring nature andprotecting biodiversity are interconnecting and mutuallyreinforcing objectives. Effective climate changemitigation requires protecting and restoring naturalsystems, ensuring they are healthy and resilient. In the space of voluntary corporate accountabilityframeworks, theScience Based Targets Network(SBTN)released the initial set of science-basedtargets for freshwater and land in 2023 and plans torelease guidance for ocean science-based targets in2025. In 2024, the SBTN also released a new suite ofenabling materials and integrated its updated technicalguidance into its target-setting process. Additionally,theTaskforce on Nature-related Financial Disclosures(TNFD) published its initial recommendations for nature-related financial disclosures in 2023, along with sector-specific guidelines for various industries, including thebiotechnology and pharmaceutical sectors. and environmental impacts of business operationsand supply chains. In addition, theEU DeforestationRegulation (EU